Clinical Trials
21 trialsNCT02329080 2025-07-08
New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Completed
NCT00544115 2025-06-10
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Phase 2 Active not recruiting
NCT00057954 2023-06-28
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT00536978 2020-09-24
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01490723 2020-05-05
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01529827 2019-09-24
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
Phase 2 Completed
NCT02208037 2019-01-23
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT01789255 2018-07-24
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
National Cancer Institute (NCI)
Phase 2 Completed
NCT00245037 2017-09-27
Bu Flu TBI
OHSU Knight Cancer Institute
Phase 1/2 Completed
NCT00281879 2017-09-27
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00448357 2017-07-17
LCCC0510
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT00448201 2017-05-30
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00513474 2017-05-25
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Phase 1 Completed
NCT01118013 2017-03-24
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT01181271 2017-03-09
Tandem Auto-Allo Transplant for Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT00057811 2014-09-19
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Children's Oncology Group
Phase 2 Completed
NCT00589563 2014-09-10
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00818961 2013-12-18
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Northside Hospital, Inc.
Phase 2 Terminated
NCT00787761 2012-10-01
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Northside Hospital, Inc.
Phase 2 Completed
NCT00121186 2012-04-03
S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma
SWOG Cancer Research Network
Phase 2 Terminated